Abstract:Abstract Increased visceral fat correlates with a high risk of morbidity and mortality from diabetes and other metabolic diseases. To cope with changes of nutritional status, the adipose tissue undergoes dynamic remodeling, during which adipose derived stem cells (ADSCs) participate through cell proliferation and adipogenic differentiation into mature adipocytes. Besides, beige adipocytes formation from ADSCs, to dissipate energy as heat in mitochondrial via uncoupling protein1 (UCP1) has been proved to improve energy expenditure. Thus, modifying adipose remodeling and promoting beige adipogenesis of ADSCs in visceral fat bring much metabolic benefits. Newly listed LY3298176, an agonist targeted on glucose-dependent insulinotropic polypeptide (GIP) /glucagon-like peptide-1 (GLP-1) receptor, shows outstanding effect of reducing glucose and weight. Due to superior efficacy in dual-target agonist to GLP-1 monotherapy, and the unknown role of GIP in human visceral adipose, we aimed to clarify GIP’s role in undifferentiated ADSCs in vivo. We selected cell model derived from abdominal omental adipose tissue by obtaining ADSCs via primary culture from patients, because of wide-distributed GIP receptors in fat, and the dominant role of abdominal fat in metabolism. Then the cells were allowed to proliferate, or differentiate into adipocytes in the differentiation medium (DM), with or without co-treated with GIP or GIP3-42 (GIP receptor antagonist), followed by subsequently measurement. CCK-8, EdU incorporation, and cell cycle analysis were conducted to assess cellular proliferation. Annexin V FITC/PI stain, TUNEL and cleaved caspase3 detection were performed to evaluate apoptosis. The related signaling pathway was measured by Western blot and the validation was conducted by using pathway inhibitors followed with the above proliferation and apoptosis analysis. Besides, at the early stage of adipogenesis, mitotic clonal expansion (MCE) was reflected by cell cycle detection. Western blot analysis, quantitative real time-PCR (qRT-PCR), and Oil Red O staining were performed to evaluate adipogenesis. We found that GIP facilitated ADSCs viability and DNA synthesis, accelerated cell cycle progress and reduced palmitate-induced apoptosis by promoting phosphorylation of ERK1/2, AKT, PKA and AMPK. We further confirmed that ADSCs after confluence underwent MCE once induced by DM. GIP also modified adipogenesis by accelerating MCE, upregulating core transcription factor (PPARγ and C/EBPα), increasing beige-related markers (UCP1, PGC1α, PRDM16, et al) while suppressing white-related genes (ZFP423 and TLE3). In summary, we illustrated the efficacies of GIP on proliferation, apoptosis and adipogenesis (especially the beige adipocyte formation) of ADSCs, providing evidence of the additional metabolic benefits of GIP/GLP-1 dual-target agonist over GLP-1 agonist monotherapy in vivo.

GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis

Glucagon-like Peptide 1 Regulates Adipogenesis in 3T3-L1 Preadipocytes

Liraglutide Suppresses Proliferation and Induces Adipogenic Differentiation of 3T3-L1 Cells Via the Hippo-YAP Signaling Pathway

Liraglutide Modulates Lipid Metabolism Via ZBTB20-LPL Pathway

Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice

1751-P: Induction of Sirt1-AMPK Pathway by GLP-1RA Liraglutide Reduces Hepatic Lipid Accumulation and Insulin Resistance

The Role of a Glucagon-Like Peptide-1 Receptor Agonist in Visceral and Subcutaneous Fat Redistribution

The Key Role of a Glucagon-Like Peptide-1 Receptor Agonist in Body Fat Redistribution

Glucagon-like peptide-1 receptor mediates the improvement in glycolipid metabolism disorder via AKT and AMPK signalling pathways in L02 cells with insulin resistance

SAT-LB103 Glucose-Dependent Insulinotropic Polypeptide Promotes Proliferation, Inhibits Apoptosis and Modifies Adipogenesis in Human Omental Adipose-Derived Stem Cells

GLP-1RA Promotes Brown Adipogenesis of C3H10T1/2 Mesenchymal Stem Cells Via the PI3K-AKT-mTOR Signaling Pathway

Glp-1 Receptor Activation Inhibits Vldl Production And Reverses Hepatic Steatosis By Decreasing Hepatic Lipogenesis In High-Fat-Fed Apoe*3-Leiden Mice

Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy

794-P: Effect of Liraglutide on Abdominal Fat Distribution and Glucose Metabolism in Chinese Patients with Obesity

Effect of GLP-1 receptor agonist on lipolysis in adipose tissue of obese mice and its underlying mechanism

Effects of GLP-1 Receptor Agonist on Glycolipid Metabolism and Micro Inflammatory Status in Patients with Abdominal Obesity and Type 2 Diabetes

Liraglutide Reduces Lipogenetic Signals in Visceral Adipose of Db/db Mice with AMPK Activation and Akt Suppression

Glp-1 Analog, Liraglutide, Ameliorates Hepatic Steatosis and Cardiac Hypertrophy in C57BL/6J Mice Fed a Western Diet.

Effects and Mechanisms of GLP-1 on Fatty Acid Metabolism in Insulin-Resistant 3T3-L1 Adipocytes

Liraglutide may affect visceral fat accumulation in diabetic rats via changes in FTO, AMPK, and AKT expression

Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway